TransMedics: Despite Earnings Miss, Growth Story Remains Intact
TransMedics Group, Inc. continues to be rated a 'Strong Buy' despite a significant drop in stock price and a miss in Q1 earnings. The company is focusing on long-term growth strategies, including portfolio expansion and a rollout in Europe. Revenue for Q1 2026 showed a year-over-year increase of 21%.
- ▪TransMedics experienced a 50% decline in stock price but remains a Strong Buy.
- ▪The company is expanding its portfolio with new offerings and targeting the European market.
- ▪Q1 2026 revenue grew by 21% compared to the previous year.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://seekingalpha.com/"},{"@type":"ListItem","position":2,"name":"Stock Ideas","item":"https://seekingalpha.com/stock-ideas"},{"@type":"ListItem","position":3,"name":"Long Ideas","item":"https://seekingalpha.com/stock-ideas/long-ideas"},{"@type":"ListItem","position":4,"name":"Healthcare ","item":"https://seekingalpha.com/stock-ideas/healthcare"}]}{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4908576-transmedics-despite-earnings-miss-growth-story-remains-intact"},"author":{"@type":"Person","name":"Conviction…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Seeking Alpha.
Discussion
0 commentsMore from Seeking Alpha
